Synonyms: VX-853 | VX853
Compound class:
Synthetic organic
Comment: Timcodar (VX-853) is a pyridine compound that was developed by Vertex Pharmaceuticals. It acts as a mammalian and bacterial efflux pump inhibitor. It was proposed to enhance activity of antibacterials such as rifampin, by inhibiting their efflux via bacterial efflux pumps [1,3]. It was also investigated for potential to prevent efflux of chemotherapy drugs, to enhance cancer treatment, and has been proposed as a possible antiobesity therapy [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Vertex discontinued development of VX-853 for treating infection at the preclinical stage. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00004030 | VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin | Phase 1/Phase 2 Interventional | Georgetown University |